Atara Biotherapeutics Inc. is suspending development of PINTA 745 after the peptide-antibody combination missed its primary endpoint, defined as percent change from baseline in lean body mass as measured by dual energy X-ray absorptiometry at week 12, in a phase II proof-of-concept study.